Guided Therapeutics, Inc.
Guided Therapeutics, Inc. (GTHP) Revenue
Annual & quarterly revenue history · segment & region breakdown
GTHP · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsGuided Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 10857.14% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | +10857.14% |
| 2024-12-31 | $0.00B | -$0.00B | -92.86% |
| 2023-12-31 | $0.00B | +$0.00B | +653.85% |
| 2022-12-31 | $0.00B | -$0.00B | -83.95% |
| 2021-12-31 | $0.00B | -$0.00B | -20.59% |
| 2020-12-31 | $0.00B | +$0.00B | +183.33% |
| 2019-12-31 | $0.00B | -$0.00B | -36.84% |
| 2018-12-31 | $0.00B | -$0.00B | -76.64% |
| 2017-12-31 | $0.00B | -$0.00B | -59.67% |
| 2016-12-31 | $0.00B | -$0.00B | -0.17% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Guided Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Guided Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Guided Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
GTHP revenue · 4 questionsGTHP's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 10857.14% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Guided Therapeutics, Inc. SEC filings · GAAP · Guided Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026